Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy, Anticipates Uptick Following Earnings

March 1, 2022 8:22 AM

Needham & Company analyst Ami Fadia reiterated a Buy rating and $65.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found